Sign Out
UserName
Profession Email
Profession Email
|
Dosage/Direction for Use
Nasal Active immunisation against influenza Adult: As live, attenuated quadrivalent influenza vaccine: ≤49 years 0.2 mL (0.1 mL in each nostril) as 1 dose per season. Child: As live, attenuated tetravalent influenza vaccine: 2-17 years 0.2 mL (0.1 mL in each nostril), a second dose is given after at least 4 weeks in children who have not been vaccinated previously. As live, attenuated quadrivalent influenza vaccine: 2-8 years 0.2 mL (0.1 in each nostril), a second dose is given after at least 4 weeks in children who have not been vaccinated previously; ≥9 years Same as adult dose. Parenteral Active immunisation against influenza Adult: As surface antigen, inactivated or split virion, inactivated influenza vaccine: 0.5 mL as 1 dose per season via IM or deep SC inj. Child: As surface antigen, inactivated influenza vaccine: 6-35 months 0.25 or 0.5 mL as 1 dose per season, in accordance with existing national recommendations; ≥3 years 0.5 mL as 1 dose per season. Repeat dose at least 4 weeks later if child was not previously vaccinated. As split virion, inactivated influenza vaccine: ≥5 years 0.5 mL as 1 dose per season; a 2nd dose should be given after at least 4 weeks in children <9 years who have not been previously vaccinated. Intradermal Active immunisation against influenza Adult: 18-64 years As inactivated quadrivalent influenza vaccine: 9 mcg as 1 dose per season. |
|
Contraindications
Hypersensitivity to any influenza vaccine, egg or chicken proteins. Severely immunosuppressed patients (e.g. HIV patients). Concomitant salicylate therapy (nasal).
|
|
Special Precautions
Patient with asthma, acute illness, recurrent or active wheezing (children <5 years), CV disorders, personal or family history of febrile convulsions, history of Guillain-Barre syndrome; nasal congestion (nasal). Postpone vaccination in patients with active infection or acute febrile illness. Children. Pregnancy and lactation. Monitoring Parameters Monitor for signs of anaphylaxis.
|
|
Adverse Reactions
Significant: Syncope, hyperventilation, stress-related reactions, paraesthesia, transient visual disturbance, tonic-clonic limb movements.
Cardiac disorders: Chest tightness.
Gastrointestinal disorders: Sore throat, abdominal pain, gastroenteritis, nausea, vomiting.
General disorders and administration site conditions: Irritability, lethargy, fatigue, weakness, malaise, diaphoresis; injection site reactions (e.g. erythema, bruising, swelling).
Infections and infestations: Infection, varicella.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Myalgia, chills, arthralgia, back pain.
Nervous system disorders: Headache, migraine.
Psychiatric disorders: Drowsiness.
Respiratory, thoracic and mediastinal disorders: Cough, nasal congestion, rhinorrhoea.
Skin and subcutaneous tissue disorders: Ecchymosis.
Vascular disorders: Hypertension.
Potentially Fatal: Severe hypersensitivity (e.g. anaphylaxis). |
|
ROUTE(S) : Intradermal: B
ROUTE(S) : Nasal / Parenteral: C
|
|
Drug Interactions
Decreased immunological response with immunosuppressants.
Potentially Fatal: Concomitant treatment with salicylates (e.g. aspirin) may lead to Reye's syndrome (nasal). |
|
Lab Interference
False-positive results in serology tests using enzyme-linked immunosorbent assays (ELISAs) method to detect antibodies to HIV-1, HTLV-1 and hepatitis C virus. May cause positive result on the rapid influenza diagnostic test for the 7 days after vaccine administration (nasal). May diminish diagnostic effect of tuberculin tests.
|
|
Action
Influenza virus vaccine promotes immunity to influenza virus by inducing specific antibody production.
Synonym: flu vaccine.
Onset: Within 2 weeks of vaccination. Duration: ?6-8 months. Distribution: Nasal: Distributed in the nasal cavity (approx 90%), stomach (approx 3%), brain (approx 2%), and lungs (0.4%). |
|
Storage
Intradermal: Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements. Nasal: Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements. Parenteral: Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
|
|
CIMS Class
|
